GlassScriptPhysician profile
Christopher R Horrell
NPI 1134558885
$4,997.49
in general payments reported to CMS, 2019-2025
33 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $827 · 2022: $900 · 2023: $767 · 2024: $1,128 · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,270.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,970.19 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $503.98 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $476.81 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $287.38 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $231.89 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $200.98 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $161.44 | 2025 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.35 | 2021-2025 | Relistor, Xifaxan |
| Pulmonx Corporation | $142.86 | 2022 | |
| Xeris Pharmaceuticals, INC. | $94.57 | 2021-2024 | Gvoke Hypopen |
| Aimmune Therapeutics, INC. | $77.05 | 2025 | Zenpep |
| Cequr Corporation | $76.90 | 2023 | Cequr Simplicity |
| Axsome Therapeutics, INC. | $59.89 | 2024-2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $56.08 | 2022 | |
| Exact Sciences Corporation | $50.28 | 2025 | The Cologuard Plus Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $49.69 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.44 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $46.28 | 2022 | |
| Abbott Laboratories | $40.17 | 2023-2024 | Proclaim, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $35.97 | 2021-2022 | |
| Dexcom, INC. | $31.32 | 2022-2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $29.03 | 2024 | |
| Protega Pharmaceutials INC | $28.33 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.31 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.19 | 2023 | Ztlido |
| Valinor Pharma, LLC | $16.10 | 2023 | Movantik |
| Genzyme Corporation | $15.34 | 2021 | |
| Amarin Pharma, INC. | $15.01 | 2021 | |
| Lundbeck LLC | $14.82 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $13.54 | 2023 | |
| Amgen INC. | $13.52 | 2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $12.77 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Horrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.